Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carotid Stent Firms See Another Step Into Market With Expanded Coverage

This article was originally published in The Gray Sheet

Executive Summary

Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth

You may also be interested in...



CMS Proposal For Carotid Stenting Coverage Gives A Little, Takes A Little

CMS' proposed revision to its carotid artery stenting Medicare coverage policy is a mixed blessing for manufacturers eager to reach more patients

CMS Proposal For Carotid Stenting Coverage Gives A Little, Takes A Little

CMS' proposed revision to its carotid artery stenting Medicare coverage policy is a mixed blessing for manufacturers eager to reach more patients

ev3’s Protégé Joins Sprouting Field In U.S. Carotid Stent Market

Plymouth, Minn.-based ev3 Inc. joined a growing number of players in the U.S. carotid stent market with the Jan. 25 nationwide launch of its Protégé RX immediately following FDA approval

Related Content

UsernamePublicRestriction

Register

MT023962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel